Cormedix Inc Revenue Growth Rates (CRMD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cormedix Inc   (NASDAQ: CRMD)
 

CRMD's Revenue Growth by Quarter and Year

Cormedix Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRMD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 101.93
1st Quarter March 117.12
FY 219.05

CRMDs Annual Revenue
Cormedix Inc 's Revenue in the fiscal year 2025 $ 39.08 millions
Cormedix Inc 's Revenue in the fiscal year 2024 $ 43.47 millions
Cormedix Inc 's Revenue in the fiscal year 2023 $ 0.00 millions
Cormedix Inc 's Revenue in the fiscal year 2022 $ 0.07 millions
Cormedix Inc 's Revenue in the fiscal year 2021 $ 0.19 millions




CRMD Revenue second quarter 2026 Y/Y Growth Comment
Cormedix Inc reported Revenue surge of 156.49% year on year in the second quarter 2026, to $ 101.93 millions, this is lower than Cormedix Inc 's recent average Revenue surge of 13270.72%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue growth. While Cormedix Inc ' s Revenue doubling of 156.49% ranks overall at the positon no. 180 in the second quarter 2026.


CRMD Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 1022.34 % - -
3rd Quarter September - 12774.07 % - -
2nd Quarter June 156.49 % - - -
1st Quarter March 275.26 % - - -50 %
FY   - 2376.37 % 40800 % -

Financial Statements
Cormedix Inc 's second quarter 2026 Revenue $ 101.93 millions CRMD's Income Statement
Cormedix Inc 's second quarter 2025 Revenue $ 39.74 millions Quarterly CRMD's Income Statement


CRMD Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 23.34 % 1314.81 % -
3rd Quarter September - 162.41 % - -
2nd Quarter June -12.97 % 27.33 % - -
1st Quarter March -8.94 % 172.34 % - 200 %
FY (Year on Year)   - 2376.37 % 40800 % -


Back to CRMD Growth rate Comparisons >> Back to CRMD Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #57
Overall #180

Revenue Y/Y Growth Statistics
High Average Low
529095.65 % 13270.72 % -100 %
(Jun 30 2026)   (Jun 30 2020)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #57
Overall #180
Revenue Y/Y Growth Statistics
High Average Low
529095.65 % 13270.72 % -100 %
(Jun 30 2026)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Cormedix Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
179900 % 4993.55 % -100 %
(Mar 31 2016)  


CRMD's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Cormedix Inc disclosed drop in Revenue from the first quarter by -12.97% to $ 101.93 millions, from $ 117.12 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 136 other companies have achieved higher Revenue quarter on quarter growth. While Cormedix Inc 's Revenue growth quarter on quarter, overall rank is 3000.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #137
Healthcare Sector #391
Overall #3000
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #137
Healthcare Sector #391
Overall #3000
Revenue Q/Q Growth Statistics
High Average Low
179900 % 4993.55 % -100 %
(Mar 31 2016)  


CRMD's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Cormedix Inc disclosed drop in Revenue from the first quarter by -12.97% to $ 101.93 millions, from $ 117.12 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 136 other companies have achieved higher Revenue quarter on quarter growth. While Cormedix Inc 's Revenue growth quarter on quarter, overall rank is 3000.


Cormedix Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 451.94 $ 389.75 $ 303.84 $ 186.68 $ 83.21
Y / Y Revenue Growth (TTM) 443.14 % - - - -
Year on Year Revenue Growth Overall Ranking # 45 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 15.96 % 28.28 % 62.76 % 124.35 % -
Seq. Revenue Growth (TTM) Overall Ranking # 134 # 100 # 91 # 0 # 0


Cumulative Revenue growth Comment
With 443.14% annual Revenue growth, Cormedix Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 45.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 23
Healthcare Sector # 13
Overall # 45

Revenue TTM Y/Y Growth Statistics
High Average Low
443.14 %
 34.05 %
-70.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 42
S&P 500 # 134
Cumulative Revenue growth Comment
With 443.14% annual Revenue growth, Cormedix Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 45.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 23
Healthcare Sector # 13
Overall # 45

Revenue TTM Y/Y Growth Statistics
High Average Low
443.14 %
34.05 %
-70.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 42
S&P 500 # 134




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CRMD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions


About Cormedix Inc Revenue Growth Rates (CRMD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cormedix Inc (CIK 1410098).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001410098-26-000056
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cormedix Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.